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Introduction

57
Preterm birth (PTB), defined as birth before 37 weeks of pregnancy, accounts for 5-18% of all 58 recorded births worldwide (1). Importantly, PTB is associated with long-term neurodevelopmental 59 outcomes and an increased risk for respiratory and gastrointestinal complications in the offspring (2).
60
The major obstetric precursor leading to PTB is spontaneous preterm labour, the outcome of preterm 
72
Steroid hormones are currently the focus of much interest for PTB treatment and prevention.
73
Prophylactic administration of vaginal progesterone (P) to pregnant women at high risk has been
74
shown to reduce the rate of PTB by 50% (7). Our research group has previously demonstrated that 75 exposure of spontaneously contracting myometrial strips to progesterone (P) resulted in a rapid (<30 76 minutes) reduction in the amplitude and integral of contraction, in line with P's well-established role 77 in maintenance of pregnancy (8). In addition to P, one study reported that androgens in micromolar 78 doses also relaxed human myometrial contractions ex vivo (9). We have recently reviewed all the 79 evidence for a role of androgens in maintenance of pregnancy (10). Considering that a) tocolytics in 80 current use delay delivery only by 24 hours to 7 days, b) P supplementation prevents only one-third of 81 all recurrent PTBs and finally c) androgens produced by the placenta could be involved in the 82 maintenance of pregnancy, we hypothesised that androgens should be investigated as novel PTB 83 therapeutic agents. However, there is limited evidence on the efficacy of androgens, and the 84 mechanism of action of androgens in preventing uterine contractions is poorly understood. 
90
and, hence, reduction in the phosphorylation of MLC.
91
Materials and Methods
92
Human Tissue
93
Biopsies were obtained from the upper margin of the lower segment of myometrium from women 94 undergoing elective caesarean section (ECS) as previously described (11) 
124
Organ bath
125
The assessment of myometrial contractility utilising organ bath is well established (8, 13, 15, 16 
177
Data was analysed as indicated in the figure legends and presented as the mean ± SEM; p<0.05 was 178 considered statistically significant.
179
Results
180
Androgens inhibit the contraction of uterine myocytes embedded in collagen gels
181
We set out to explore the effect of lipid soluble androgens DHT and T and of the cell-impermeable 
193
( Figure 1E ) and 48 hours ( Figure 1F ), suggesting that the T-mediated inhibition of contraction is
194
unlikely to be cell-surface receptor mediated. In addition, the finding that DHT (50 μM) prevented the 195 basal contraction of PHM1-41s in which expression of the AR was silenced (hAR-PHM1-41s; Figure 1 G, H) suggested that AR is unlikely to be involved in the induction of relaxation by androgens.
197
Finally, a viability assay ruled out the hypothesis that androgens at high micromolar doses induce cell 198 death ( Figure 1I ). We conclude that long (>24 hours) exposure to lipid soluble androgens can inhibit 199 uterine smooth muscle contraction in vitro via an AR-independent mechanism that is likely to be 200 mediated by penetration through the cell membrane.
201
Androgens relax human and mouse uterine smooth muscle ex vivo
202
We examined the effect of short-term ( 
214
The organ bath studies combined with the gel contraction studies allowed the observation that lipid 215 soluble androgens induce a rapid but sustained inhibition of uterine contractions. 
250
Discussion
251
A relaxant effect of androgens on smooth muscle contraction has been reported in different systems (19) (20) (21) (22) (23) 
252
314
A female fetus would only be in danger of virilisation if the androgen was administered during the 315 masculinisation window, which is reported to exist during the first trimester of pregnancy (36).
316
Conversely, animal studies have informed that maternal androgen excess is associated with the 317 development of PCOS in the offspring (37). However, in the majority of these studies, androgen 
322
Further basic understanding of the dose response and the mechanism of action of androgens on uterine
323
contractions are required to inform the design of preclinical studies on androgens as tocolytic agents.
324
Notably, the IC50 values generated here could help design experiments whereby administration of
325
DHT or T to existing mouse models of PTB (40) 
